PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.47%
Cash & equivalents declining -7.47% while Biotechnology shows -11.32% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-7.47%
Cash + STI yoy growth 0.5-0.75x the Biotechnology median of -10.11%. Guy Spier would be cautious about potential underfunding of liquidity.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.14%
0.75-0.9x the Biotechnology median of -8.76%. John Neff wonders if the firm invests less in working capital or sales growth is slower.
-20.34%
PP&E growth below half of Biotechnology median of 0.00%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.34%
≥ 1.5x the Biotechnology median of -0.62%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
-7.25%
Near the Biotechnology median of -7.11%. Charlie Munger sees typical asset growth among the sector.
-4.95%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
-36.48%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
No Data
No Data available this quarter, please select a different quarter.
-627.15%
Below half Biotechnology median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
-89.58%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-16.33%
Above 1.5x Biotechnology median of -2.51%. Jim Chanos suspects potential working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-33.33%
Above 1.5x Biotechnology median of -1.68%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-16.34%
Above 1.5x Biotechnology median of -1.66%. Jim Chanos suspects an alarming rise in overall leverage.
No Data
No Data available this quarter, please select a different quarter.
-2.01%
Below half Biotechnology median of -6.09%. Jim Chanos suspects poor profitability or large dividend drains.
100.00%
Above 1.5x Biotechnology median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
-100.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
-6.40%
0.75-0.9x Biotechnology median of -8.15%. John Neff wonders if the firm's equity growth lags peers.
-7.25%
Near Biotechnology median of -7.08%. Charlie Munger sees standard yoy changes matching sector norms.
No Data
No Data available this quarter, please select a different quarter.
-36.45%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
7.35%
50-75% of Biotechnology median 14.44%. Mohnish Pabrai notes comparatively lower net debt growth.